Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1310

Sort by

Sort Order Select

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Blood (2019) 134 (Supplement_1): 691.

https://doi.org/10.1182/blood-2019-123465

Published: 2019

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

Journal Articles

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

Alessandra Iurlo, MD PhD, Mario Annunziata, MD, Francesco Albano, MD, Luigia Luciano, MD, Raffaele Spadano, MD, Anna Rita Scortechini, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD, Monia Lunghi, MD PhD, Alessandra Malato, MD PhD, Nicola Di Renzo, MD, Alfonso Piciocchi, Angela Pellegrino, MSc, Claudia Galimberti, Robin Foà, MD, Massimo Breccia, MD

Blood (2019) 134 (Supplement_1): 1652.

https://doi.org/10.1182/blood-2019-126098

Published: 2019

Journal Articles

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1653.

https://doi.org/10.1182/blood-2019-131599

Published: 2019

Journal Articles

Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma

Liang Lin, PhD, Lijie Xing, MD, Shih-Feng Cho, MD PhD, Kenneth Wen, Phillip A Hsieh, Metin Kurtoglu, MD PhD, Yi Zhang, C Andrew Stewart, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 1811.

https://doi.org/10.1182/blood-2019-121595

Published: 2019

Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1655.

https://doi.org/10.1182/blood-2019-125368

Published: 2019

Journal Articles

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

B. Douglas Smith, MD, Tim H Brümmendorf, MD, Gail J. Roboz, MD, Carlo Gambacorti-Passerini, MD, Aude Charbonnier, Andrea Viquiera, Eric Leip, PhD, Frank Giles, MD, Thomas Ernst, MD, Andreas Hochhaus, MD, Gianantonio Rosti, MD

Blood (2019) 134 (Supplement_1): 1650.

https://doi.org/10.1182/blood-2019-122230

Published: 2019

Journal Articles

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Roland Jäger, PhD, Elisabeth Fuchs, Edith Bogner, Jelena D. Milosevic Feenstra, PhD, Kurt Krejcy, MD, Christoph Klade, PhD, Michael Zoerer, PhD, Heinz Gisslinger, MD, Robert Kralovics, PhD

Blood (2019) 134 (Supplement_1): 1685.

https://doi.org/10.1182/blood-2019-130139

Published: 2019

Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Blood (2019) 134 (Supplement_1): 1865.

https://doi.org/10.1182/blood-2019-122765

Published: 2019

Journal Articles

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Jonathan L. Kaufman, MD, Saad Z. Usmani, MD, Jesús San-Miguel, Nizar Bahlis, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jon Ukropec, PhD, Thomas Renaud, Sonali Trivedi, Rachel Kobos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1866.

https://doi.org/10.1182/blood-2019-123483

Published: 2019

Journal Articles

Risk of Serious Infections with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Somedeb Ball, MD, Tapas Ranjan Behera, Sariya Wongsaengsak, MD, Nuvneet Khandelwal, MD, Rajshekhar Chakraborty, MD

Blood (2019) 134 (Supplement_1): 1841.

https://doi.org/10.1182/blood-2019-125464

Published: 2019

Journal Articles

Early Discontinuation (ED) of Therapy and Treatment Patterns Among Chronic Lymphocytic Leukemia (CLL) Patients: Findings from a Linked Claims and Electronic Health Record (EHR) Dataset

Seth Kuranz, MPH, Jennifer Stacey, BS, Sierra Luciano, BS

Blood (2019) 134 (Supplement_1): 1749.

https://doi.org/10.1182/blood-2019-130848

Published: 2019

Journal Articles

Evaluation of Virus-Specific T Cell Responses in Patients Affected with Myeloproliferative Neoplasms Treated with Ruxolitinib

Elisa Rumi, MD, Chiara Cavalloni, MD, Giuditta Comolli, Virginia Valeria Ferretti, Irene Cassaniti, Daniela Pietra, PhD, Chiara Trotti, MD, Michele Ciboddo, MD, Melania Degli Antoni, Milena Furione, Fausto Baldanti, MD, Luca Arcaini, Mario Cazzola, MD

Blood (2019) 134 (Supplement_1): 1660.

https://doi.org/10.1182/blood-2019-127994

Published: 2019

Journal Articles

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, MD, Andrzej Jakubowiak, MD PhD, Cristina Gasparetto, MD, Robert F. Cornell, MD MS, Heike I. Krupka, PhD PMP, Daniel Navarro, MD MSc, Alison J. Forgie, DPhil, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Jeffrey Chou, MD PhD, Abraham Leung, MD, Alexander M. Lesokhin, MD

Blood (2019) 134 (Supplement_1): 1869.

https://doi.org/10.1182/blood-2019-121805

Published: 2019

Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA

Blood (2019) 134 (Supplement_1): 1845.

https://doi.org/10.1182/blood-2019-126606

Published: 2019

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Laurence Legros, MD PhD, Franck E Nicolini, MDPhD, Gabriel Etienne, MD PhD, Philippe Rousselot, MDPhD, Delphine Rea, MD, Stephane Giraudier, MD PhD, Agnès Guerci, MD PhD, Francoise Huguet, MD, Martine Gardembas, MD, Jean-Christophe Ianotto, MD PhD, Martine Escoffre-Barbe, MD, Valerie Coiteux, MD, Bruno Varet, MD, Stephane Morisset, BioStat, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 28.

https://doi.org/10.1182/blood-2019-123719

Published: 2019

NARROW

AL patients don’t dare go without dara

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Risk of Serious Infections with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Early Discontinuation (ED) of Therapy and Treatment Patterns Among Chronic Lymphocytic Leukemia (CLL) Patients: Findings from a Linked Claims and Electronic Health Record (EHR) Dataset

Evaluation of Virus-Specific T Cell Responses in Patients Affected with Myeloproliferative Neoplasms Treated with Ruxolitinib

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only